Aluminum Oxide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Aluminum Oxide
- Aluminum Oxide: From an Antacid Ingredient (Indication Not Specified in Licences) to Rheumatoid Arthritis
Aluminum Oxide: From an Antacid Ingredient (Indication Not Specified in Licences) to Rheumatoid Arthritis
One-Sentence Summary
Aluminum oxide is marketed in Singapore as an aluminium hydroxide antacid suspension, although the licence records do not state an approved indication. The TxGNN model predicts it may be effective for rheumatoid arthritis, but there are 0 clinical trials and only 1 publication (a 1978 hip implant report), which does not support a therapeutic effect. This is essentially a computational prediction with no real supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, aluminum oxide is the active component of aluminium hydroxide oral suspensions registered in Singapore. These products are antacid mixtures, but the licence records do not list an approved indication.
No pharmacological mechanism links aluminum oxide to rheumatoid arthritis. The only publication found describes an alumina ceramic hip implant. This is a structural implant material, not a disease-modifying therapy. Any connection is indirect: patients with joint destruction, which can include rheumatoid arthritis, may receive joint replacements.
The high TxGNN score most likely reflects proximity in the knowledge graph, not therapeutic activity. The other nine top predictions (for example brachydactyly-syndactyly syndrome, thrombotic disease and several haemoglobin and coagulation disorders) have no trials or literature and no plausible mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 729270 | 1978 | Device/surgical technique report | Clin Orthop Relat Res | Cement-free alumina ceramic double-cup hip prosthesis in 9 patients (11 hips). Early loosening of the femoral component occurred in several cases. It is not a drug study and does not address rheumatoid arthritis treatment. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02614P | Aluminium Hydroxide Mixture BP 4% w/w | Suspension | Not stated |
| SIN08783P | Alutacid Antacid Mixture 4% w/w | Suspension | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials, the single publication concerns an implant material rather than a drug effect, and no plausible mechanism has been identified. Package insert safety data have also not been reviewed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator
- Mechanism of action data for aluminum oxide
- Evidence of a biological link to rheumatoid arthritis (preclinical or clinical)
- Confirmation of the approved indications of the registered products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.